{
    "symbol": "CELC",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-16 22:49:11",
    "content": " Subject to meet eligibility criteria and do not have confirmed PIK3CA mutations will be randomly assigned on a 1:1:1 basis to receive a regimen of either gedatolisib, palbociclib and fulvestrant in Arm A; gedatolisib and fulvestrant in Arm B; or fulvestrant in Arm C. Subjects who meet eligibility criteria and have confirmed PIK3CA mutations will be randomly assigned on a 1:1 basis to receive a regimen of either gedatolisib, palbociclib and fulvestrant in Arm D; or alpelisib and fulvestrant in Arm E. We are receiving the supply of palociclib for this trial from Pfizer at no cost to Celcuity."
}